Recombinant Anti-Nuclear Matrix Protein p84 antibody [EPR5662(2)] (ab131268)


  • Product name

    Anti-Nuclear Matrix Protein p84 antibody [EPR5662(2)]
    See all Nuclear Matrix Protein p84 primary antibodies
  • Description

    Rabbit monoclonal [EPR5662(2)] to Nuclear Matrix Protein p84
  • Host species

  • Tested applications

    Suitable for: ICC/IF, WB, IHC-Pmore details
    Unsuitable for: Flow Cyt or IP
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human Nuclear Matrix Protein p84 aa 350-450. The exact sequence is proprietary.

  • Positive control

    • HeLa, U-87 MG, 293T and HepG2 whole cell lysate (ab7900); Human breast carcinoma tissue; HeLa cells.
  • General notes



    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab131268 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration.
WB 1/10000 - 1/50000. Detects a band of approximately 84 kDa (predicted molecular weight: 76 kDa).
IHC-P 1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. (Heat to 98°C, allow to cool for 10-20 minutes)
  • Application notes
    Is unsuitable for Flow Cyt or IP.
  • Target

    • Function

      Component of the THO subcomplex of the TREX complex. The TREX complex specifically associates with spliced mRNA and not with unspliced pre-mRNA. It is recruited to spliced mRNAs by a transcription-independent mechanism. Binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export. The recruitment occurs via an interaction between THOC4 and the cap-binding protein NCBP1. DDX39B functions as a bridge between THOC4 and the THO complex. The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. The recruitment of the TREX complex to the intronless viral mRNA occurs via an interaction between KSHV ORF57 protein and THOC4.
      Regulates transcriptional elongation of a subset of genes. Participates in an apoptotic pathway which is characterized by activation of caspase-6, increases in the expression of BAK1 and BCL2L1 and activation of NF-kappa-B. This pathway does not require p53/TP53, nor does the presence of p53/TP53 affect the efficiency of cell killing. Activates a G2/M cell cycle checkpoint prior to the onset of apoptosis. Apoptosis is inhibited by association with RB1.
    • Tissue specificity

      Ubiquitous. Expressed in various cancer cell lines. Expressed at very low levels in normal breast epithelial cells and highly expressed in breast tumors. Expression is strongly associated with an aggressive phenotype of breast tumors and expression correlates with tumor size and the metastatic state of the tumor progression.
    • Sequence similarities

      Contains 1 death domain.
    • Domain

      An intact death domain is needed for apoptosis.
    • Post-translational

      Expression is altered specifically during apoptosis and is accompanied by the appearance of novel forms with smaller apparent molecular mass.
    • Cellular localization

      Cytoplasm and Nucleus speckle. Nucleus > nucleoplasm. Nucleus matrix. Cytoplasm. Can shuttle between the nucleus and cytoplasm. Nuclear localization is required for induction of apoptotic cell death. Translocates to the cytoplasm during the early phase of apoptosis execution.
    • Information by UniProt
    • Database links

    • Form

      Nuclear (Isoform 1) and Cytoplasmic (Isoform 1 and 2).
    • Alternative names

      • hTREX84 antibody
      • Death domain containing protein p84N5 antibody
      • HPR 1 antibody
      • HPR1 antibody
      • hTREX84 antibody
      • Nuclear matrix protein p84 antibody
      • P84 antibody
      • p84N5 antibody
      • Tho 1 antibody
      • THO complex 1 antibody
      • THO complex subunit 1 antibody
      • Tho1 antibody
      • THOC 1 antibody
      • Thoc1 antibody
      • THOC1_HUMAN antibody
      see all


    • All lanes : Anti-Nuclear Matrix Protein p84 antibody [EPR5662(2)] (ab131268) at 1/10000 dilution

      Lane 1 : HeLa cell lysate
      Lane 2 : U-87 MG cell lysate
      Lane 3 : 293T cell lysate
      Lane 4 : HepG2 cell lysate

      Lysates/proteins at 10 µg per lane.

      All lanes : Goat anti-Rabbit HRP at 1/2000 dilution

      Predicted band size: 76 kDa

    • Immunofluorescent staining of HeLa cells labelling Nuclear Matrix Protein p84 with ab131268 at 1/100 dilution.
    • Immunohistochemical analysis of paraffin embedded human breast carcinoma tissue labeling Nuclear Matrix Protein p84 with ab131268 at 1/50 dilution.

      Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

    • Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling Nuclear Matrix Protein p84 with purified ab131268 at 1/120 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.


    This product has been referenced in:

    • Song XL  et al. miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3ß. Biomed Pharmacother 99:369-374 (2018). WB, RT-PCR . Read more (PubMed: 29358129) »
    • Chen Z  et al. Loss of Fezf2 promotes malignant progression of bladder cancer by regulating the NF-?B signaling pathway. Lab Invest 98:1225-1236 (2018). Read more (PubMed: 29925938) »
    See all 6 Publications for this product

    Customer reviews and Q&As

    Western blot
    Human Cell lysate - whole cell (nasopharyngeal carcinoma)
    Gel Running Conditions
    Reduced Denaturing (7.5)
    Loading amount
    20 µg
    nasopharyngeal carcinoma
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 23°C

    Venus Man

    Verified customer

    Submitted Jan 13 2017

    For licensing inquiries, please contact

    Sign up